Leerink Partnrs Issues Negative Outlook for ALNY Earnings

Key Points

• Leerink Partners has significantly downgraded its earnings forecast for Alnylam Pharmaceuticals, expecting a Q3 2025 EPS of $0.03, down from a previous estimate of $0.38.
• Despite the downgraded outlook, multiple analysts maintain a positive stance, with 24 giving the stock a Buy rating and an average target price of $457.08.
• Alnylam Pharmaceuticals recently reported a quarterly EPS of $0.32, exceeding consensus expectations and showing a year-over-year revenue increase of 17.3%.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Leerink Partnrs lowered their Q3 2025 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a research report issued on Tuesday, October 14th. Leerink Partnrs analyst M. Foroohar now expects that the biopharmaceutical company will post earnings per share of $0.03 for the quarter, down from their prior forecast of $0.38. The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals' Q4 2025 earnings at $0.81 EPS and FY2025 earnings at ($0.10) EPS.

Other analysts also recently issued reports about the company. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They set an "outperform" rating and a $370.00 target price for the company. Canaccord Genuity Group increased their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. The Goldman Sachs Group upped their target price on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a "buy" rating in a research note on Tuesday, September 16th. JPMorgan Chase & Co. cut their target price on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an "overweight" rating for the company in a research note on Monday. Finally, Chardan Capital boosted their price target on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Twenty-four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $457.08.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $470.27 on Thursday. Alnylam Pharmaceuticals has a twelve month low of $205.87 and a twelve month high of $485.28. The company has a 50-day simple moving average of $454.12 and a two-hundred day simple moving average of $349.19. The stock has a market capitalization of $61.64 billion, a price-to-earnings ratio of -190.39 and a beta of 0.36. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals's revenue was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ALNY. Bessemer Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares during the last quarter. Crossmark Global Holdings Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $275,000. Strs Ohio bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $7,781,000. GAMMA Investing LLC lifted its holdings in Alnylam Pharmaceuticals by 14.3% in the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock valued at $166,000 after buying an additional 77 shares during the period. Finally, Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $243,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,405 shares of the firm's stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $635,130.25. Following the completion of the transaction, the executive vice president owned 27,438 shares in the company, valued at $12,403,347.90. This trade represents a 4.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the business's stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the sale, the executive vice president directly owned 25,231 shares in the company, valued at approximately $11,405,673.55. This represents a 8.82% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,144 shares of company stock worth $44,160,261 over the last three months. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.